Development

APOLLO FUTURE MOBILITY GROUP announces key executive appointments and ramping up of AFMG German innovation hub to reinforce its ESO presence

Technology, Rolls-Royce Motor Cars, GLM Co. Ltd., UHNWI, Operation, Rolls-Royce, Exercise, Volkswagen, GLM, Solution, Hong Kong Exchanges and Clearing, Head, EV, State, Mercedes, OEM, HKEX, Industry, Original equipment manufacturer, Engineering, Ideation, European, Software development, Development, Specialist, Volkswagen Group, Apollo, CEO, German Operations Research Society, Communication, The Chartered Institute of Marketing, BMW, The Group, BMW Group Plant Dingolfing, Le Mans Hypercar, ESO, Brand community, Apollo Automobil, Industrial design
Thursday, September 23, 2021 - 8:11am

Also, a new AFMG Facility, opened in Wolfsburg, Germany in May, is ramping up rapidly to reinforce the Group's presence in the engineering service outsourcing ("ESO") space.

Key Points: 
  • Also, a new AFMG Facility, opened in Wolfsburg, Germany in May, is ramping up rapidly to reinforce the Group's presence in the engineering service outsourcing ("ESO") space.
  • Mr. Thorsten Falldorf has been appointed Head of Research & Development Wolfsburg, heading the AFMG German Innovation Hub, effective since 1 May 2021.
  • The AFMG German Operations facilitate the development of projects for the mobility of tomorrow and promote future innovations.
  • Apollo Future Mobility Group Limited (HKEx stock code: 860) is a leading integrated mobility technology solution provider with proprietary and disruptive mobility technologies.

Successful Test Demonstrates Aerojet Rocketdyne Arkansas Site Ready to Produce Large Solid Rocket Motors

Workforce, Utah Test and Training Range, Rocketdyne, MCAT, Development, Aerojet Rocketdyne Holdings, Twitter, AJRD, Aerojet Rocketdyne, NYSE, Demo, GLOBE, 3D printing
Thursday, September 23, 2021 - 12:40am

CAMDEN, Ark., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Aerojet Rocketdyne recently conducted a solid rocket motor test firing that demonstrated the successful transition of large solid rocket motor mix, cast and test operations from Sacramento, California, to its Camden, Arkansas, site.

Key Points: 
  • CAMDEN, Ark., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Aerojet Rocketdyne recently conducted a solid rocket motor test firing that demonstrated the successful transition of large solid rocket motor mix, cast and test operations from Sacramento, California, to its Camden, Arkansas, site.
  • Aerojet Rocketdyne continues to advance its decades of work delivering large solid rocket motors, leveraging new facilities and innovative technology and materials, said Eileen P. Drake, Aerojet Rocketdyne CEO and president.
  • Our Camden site is now proven ready to support the nations defense requirements for large solid rocket motors.
  • Aerojet Rocketdyne has produced large solid rocket motors for critical defense and space programs for decades.

Clean Air Metals Files Second Quarter 2021 Interim Financial Statements

Fortification, North American Palladium, Metal, Red Rock, PPE, Palladium, Sale, TSX Venture Exchange, Mission statement, Platinum, Conversation, Impala, Métis, Development, Lac, Fort William First Nation, Personal protective equipment, Geology, CEO, Legislation, Company, Mining, Agreement, Personal Protective Equipment at Work Regulations 1992, SEDAR, COVID-19, Area studies, Panorama, VP, Maintenance, National instrument, Forward-looking statement, Copper, First Nations, Impala Platinum, British Columbia v Imperial Tobacco Canada Ltd, Travel, Oil
Wednesday, September 22, 2021 - 11:37pm

Clean Air Metals continued to apply COVID-19 avoidance and personal protection measures for its geological staff, drilling contractor and service suppliers during the third quarter.

Key Points: 
  • Clean Air Metals continued to apply COVID-19 avoidance and personal protection measures for its geological staff, drilling contractor and service suppliers during the third quarter.
  • About Clean Air Metals Inc.
    Clean Air Metals' flagship asset is the 100% owned, high grade Thunder Bay North Project, a platinum, palladium, copper, nickel project located near theCity of Thunder Bay, Ontarioand the Lac des Iles Mine owned by Impala Platinum.
  • Abraham Drost, Chief Executive Officer of Clean Air Metals Inc.
  • Any statements that express predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."

Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2

B.1.1.7, Mouse, Therapy, Infection, Cancer, Koch Institute, Vaccine, Compliance, Biomedicine, Amplifier, MIT, Spike, Elicio Berriz, Immunity, FDA, Patient, Engineering, Development, Epitope, Koch Institute for Integrative Cancer Research, Immune system, Immunology, Biomedical engineering, Immunotherapy, Lymph, Disease, Vaccination, COVID-19, Antigen, Severe acute respiratory syndrome coronavirus 2, CpG, Darrell Irvin, RBD, Safety, KRAS, Laboratory, Massachusetts Institute of Technology, Forward-looking statement, AMP, Massachusetts, GLOBE, Pharmaceutical industry
Wednesday, September 22, 2021 - 8:22pm

We are encouraged by these positive results for ELI-005 demonstrating that delivery of AMP-CpG adjuvant to the lymph nodes induces both cellular and humoral responses to SARS-CoV-2 antigens.

Key Points: 
  • We are encouraged by these positive results for ELI-005 demonstrating that delivery of AMP-CpG adjuvant to the lymph nodes induces both cellular and humoral responses to SARS-CoV-2 antigens.
  • This dual response is critical in developing broad protective immunity in patients, said Peter DeMuth, Ph.D., vice president of research at Elicio Therapeutics.
  • We believe our AMP lymph node targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes.
  • Elicio is engineering lymph node targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.

ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors

Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Science, University of North Dakota School of Medicine and Health Sciences, ImmunoGen, BLA, School, BPDCN, Annual report, Security (finance), Board of directors, Private Securities Litigation Reform Act, Drug, U.S. Securities and Exchange Commission, Cancer, Patient, Outline of health sciences, Development, Glycomimetic, Board, Senior, Bachelor of Science in Human Biology, Compugen (Israeli company), FAAP, American Academy, IMGN, George Washington University School of Medicine & Health Sciences, Pediatrics (journal), Company, Control, Stanford University, COVID-19, Acute myeloid leukemia, View, Research, Lymphatic system, George Washington University, BioCryst Pharmaceuticals, Industry, Director, Vaccine, Pharmaceutical industry
Wednesday, September 22, 2021 - 9:01pm

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors.
  • "Helen joins ImmunoGen's Board of Directors at an exciting time, as we advance multiple programs in the clinic and transform ImmunoGen into a fully integrated oncology company with the potential to launch two innovative ADCs next year," said Stephen McCluski, ImmunoGen's Chairman of the Board of Directors.
  • Dr. Thackray has over 25 years of biopharmaceutical, clinical research, and bench research experience.
  • Dr. Thackray stated, "ImmunoGen has established a leadership position in ADCs and built a strong pipeline targeting solid tumors and hematologic malignancies.

Medistar Corporation and Voyages Behavioral Health Announce Development of a Behavioral Health Hospital in Pensacola

University system, Health, Mental disorder, Trauma, Partnership, Texas Medical Center, Business intelligence, PAM, National Alliance on Mental Illness, InterContinental, Hospital, Patient, Population, Mental health, National Alliance, Development, HEALTH, Senior, Acquisition, COVID-19, Research, Education, NAMI, Medical Center, SVP, COO, Social, EVP, Texas A&M University System, GLOBE
Wednesday, September 22, 2021 - 6:00pm

PENSACOLA, Fla., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Medistar Corporation ("Medistar") and Voyages Behavioral Health ("Voyages"; an affiliate of PAM Health) are pleased to announce the development of Voyages Behavioral Health of Pensacola, a state-of-the-art behavioral health hospital.

Key Points: 
  • PENSACOLA, Fla., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Medistar Corporation ("Medistar") and Voyages Behavioral Health ("Voyages"; an affiliate of PAM Health) are pleased to announce the development of Voyages Behavioral Health of Pensacola, a state-of-the-art behavioral health hospital.
  • When completed in 2022, Voyages Behavioral Health of Pensacola will be one of the first hospitals to integrate inpatient medical and psychiatric care.
  • Identifiying a need in behavioral health services across the country, PAM Health established Voyages Behavioral Health to offer an additional service line and specialized care to this underserved patient population.
  • Voyages Behavioral Health chose Pensacola to provide much-needed services in the growing Pensacola MSA (Pensacola-Ferry Pass-Brent, FL metropolitan statistical area), which has a population of over 500,000.

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

Gene editing, Cancer, Royal college, Patient, University of Alberta, Development, Royal College of Physicians and Surgeons of Canada, Physician, Surgeon, Biochemistry, Head, Medicine, Glossary, University, Roivant Sciences, Clinical and Translational Science Award, Gilead Sciences, Amgen, Oncology, Safety, Internal medicine, Degenerative disease, Survival, Kite Pharma, NYSE, GLOBE, Pharmaceutical industry
Wednesday, September 22, 2021 - 3:07pm

as its Chief Medical Officer, effective September20, 2021.

Key Points: 
  • as its Chief Medical Officer, effective September20, 2021.
  • We welcome Roger and look forward to collaborating with him in working to transform the way our targeted diseases are treated.
  • Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma, a subsidiary of Gilead Sciences.
  • Previously, he held key positions at Roivant Sciences, where he was Chief Medical Officer and Executive Vice President and Head of Research and Development, Cell Design Labs, where he served as Chief Medical Officer, and Amgen, where he served as Global Product General Manager, Translational Sciences.

Guerbet: 2021 half-year results

Food, Therapy, H1, Artificial intelligence, Review, COVID-19, Micro, Diagnosis, Development, Agent handling, Solution, European Medicines Agency, Euronext Paris, EBITDA, Depreciation, Liver cancer, Board, AI, AMF, US Foods, Group, COVID, Acquisition, Growth, IBM Watson Health, GBT, Intelligence, Research, Forward-looking statement, Risk factor, Investment, Director, Medical device, Pharmaceutical industry, Risk management
Wednesday, September 22, 2021 - 4:54pm

The 2021 half-year financial statements, approved by the Board of Directors on September22, 2021, underwent a limited review by the statutory auditors.

Key Points: 
  • The 2021 half-year financial statements, approved by the Board of Directors on September22, 2021, underwent a limited review by the statutory auditors.
  • SG&A costs during H1 2021 were in line with H1 2020, but down 15million compared with H1 2019.
  • Thanks to this good performance, the operating result was 34.8million at June30, 2021, compared with 25.4million for the same period in 2020.
  • This increase is also explained by forex losses in 2020 not repeated in 2021.

Crayola Launches New Season of Digital-First Content in Partnership with WildBrain Spark

WildBrain, Pet, Drawing, Solution, Generation Alpha, Parent, Animation, History of Crayola crayons, AVOD, Element, YouTube, Development, IP, CEO, Life, Family, Love, YouTube Kids, Commercial, Research, WildBrain Spark, Color, PETS, Toy, Television
Wednesday, September 22, 2021 - 3:09pm

The Crayola Kingdom channel is managed globally by WildBrain Spark across YouTube and YouTube Kids and is home to the Scribble Scrubbie Pets series and all Crayola kid-targeted content.

Key Points: 
  • The Crayola Kingdom channel is managed globally by WildBrain Spark across YouTube and YouTube Kids and is home to the Scribble Scrubbie Pets series and all Crayola kid-targeted content.
  • The new season of 20 three-minute animations and 20 one-minute draw-along episodes launched on the Crayola Kingdom YouTube channel this month with new episodes released weekly.
  • This latest season of original Crayola content focuses on what kids love most about the first season as it continues to bring the world of Scribble Scrubbie Pets to life for fans."
  • Based in London, New York and Los Angeles, WildBrain Spark is part of WildBrain Ltd., a global leader in kids' and family entertainment.

Finastra introduces Total Lending Home to deliver access to its lending solutions via a single entry point

Online, Azure, Efficiency, Solution, Microsoft, Development, Total, IBM, Technology, Bank
Wednesday, September 22, 2021 - 2:00pm

LAKE MARY, Fla., Sept. 22, 2021 /PRNewswire/ -- Finastra has launched Total Lending Home, a new cloud-based portal to launch and manage the Total Lending suite of solutions. Current lending products available through the Total Lending Home portal include Fusion LaserPro, Fusion DepositPro, Fusion Compliance Reporter and ProSign Online, with additional lending products to follow.

Key Points: 
  • LAKE MARY, Fla., Sept. 22, 2021 /PRNewswire/ -- Finastra has launched Total Lending Home, a new cloud-based portal to launch and manage the Total Lending suite of solutions.
  • Current lending products available through the Total Lending Home portal include Fusion LaserPro , Fusion DepositPro, Fusion Compliance Reporter and ProSign Online, with additional lending products to follow.
  • Most significantly, as Finastra migrates its various lending solutions to the cloud, Total Lending Home will serve as the bridge to ease clients' cloud journeys, by serving as a single access point for the Total Lending product suite.
  • Total Lending Home is available at no charge for users of Finastra's Total Lending solutions.